Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PfDHODH Inhibitor
DSM267 is a triazolopyrimidine compound that preferentially inhibits Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 of 38 nM, demonstrating significant selectivity over human DHODH with an IC50 exceeding 100,000 nM. This reagent is valuable for in vitro systematic screening and characterizing the pathways of resistance evolution in Plasmodium falciparum against DHODH inhibitors. Its use supports research into antimalarial resistance mechanisms and facilitates the development of novel therapeutic strategies. -
Pf Proteasome Inhibitor
Proteasome-IN-8 is a specific inhibitor of the proteasome in Plasmodium falciparum. This compound demonstrates notable antiparasitic activity against the P. falciparum 3D7 strain. It is a valuable tool for research into the mechanisms of malaria pathogenesis and the development of therapeutic strategies targeting parasitic proteasomes. -
DHODH Inhibitor
Genz-669178 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), demonstrating an IC50 range of 0.015-0.05 μM against Plasmodium species. It effectively inhibits P. berghei and P. falciparum strains 3D7 and Dd2, with respective IC50 values of 0.068, 0.008, and 0.01 μM. In vivo studies indicate that Genz-669178 exhibits significant anti-malarial efficacy in P. berghei-infected mice, with an ED50 of 13-21 mg/kg/day, alongside favorable pharmacokinetic properties. This compound serves as a valuable tool for malaria research and drug development. -
PfDHODH/PbDHODH Inhibitor
DSM74 is a potent inhibitor of dihydroorate dehydrogenase (DHODH) in both Plasmodium falciparum (PfDHODH) and Plasmodium berghei (PbDHODH), with IC50 values of 0.28 μM and 0.38 μM, respectively. This orally active compound exhibits significant antimalarial activity, effectively inhibiting the growth of Plasmodium species in animal models. It is a valuable tool for researchers investigating the mechanisms of malaria and developing novel therapeutic strategies. -
PfDHODH Inhibitor
BRD7539 is a potent inhibitor of PfDHODH, exhibiting an IC50 value of 0.033 μM. This compound demonstrates significant efficacy against multidrug-resistant asexual blood-stage Plasmodium falciparum (Dd2 strain) with an EC50 of 0.010 μM, as well as against liver-stage Plasmodium berghei, with an EC50 of 0.015 μM. BRD7539 serves as a valuable tool for research targeting malaria drug development and resistance mechanisms. -
MMP/TACE/ADAM Inhibitor
(R)-TAPI-2 is a potent inhibitor targeting matrix metalloproteinases (MMPs), tumor necrosis factor alpha-converting enzyme (TACE), and a disintegrin and metalloproteinase (ADAM), exhibiting an IC50 value of 20 μM for MMP activity. This compound is utilized in research focused on inflammation, cancer progression, and cell signaling due to its ability to modulate proteolytic processes. Additionally, (R)-TAPI-2 has demonstrated efficacy in preventing viral entry, specifically in the context of SARS-CoV infections, making it valuable for virology studies. -
RORγ/DHODH Inhibitor
RORγ/DHODH-IN-2 is a potent dual inhibitor of RORγ and DHODH, exhibiting IC50 values of 11.9 nM and 90 nM, respectively. This compound demonstrates significant antiviral activity against multiple viruses, including SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively. RORγ/DHODH-IN-2 is ideal for research applications targeting immune signaling pathways and viral infections. -
Immunoproteasome Inhibitor
Argyrin B is a natural cyclic peptide that functions as a reversible, non-competitive inhibitor of the immunoproteasome. It demonstrates selective inhibition of the β5i and β1i subunits, with a nearly 20-fold preference for β1i over the corresponding β1c subunit found in the constitutive proteasome. In addition to its role in proteasome inhibition, Argyrin B exhibits significant antibacterial properties, making it valuable for research in immunology and antimicrobial studies. -
Nek1 Inhibitor
BSc5367 is a potent inhibitor of NIMA-related protein kinase 1 (Nek1), exhibiting an IC50 of 11.5 nM. Nek1 is integral to cell cycle regulation, DNA repair, and microtubule dynamics, with its dysfunction implicated in various conditions such as amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD), and radiotherapy-resistant cancers. This reagent is valuable for research into the molecular mechanisms underlying these diseases and for exploring potential therapeutic interventions. -
Nek7 Inhibitor
Ofirnoflastum is a selective inhibitor of the serine/threonine-protein kinase Nek7. This compound demonstrates significant anti-inflammatory properties, making it a valuable tool for research into inflammation-related pathways and diseases. Its mechanism of action and specificity towards Nek7 facilitate investigations in various cellular processes, particularly those associated with cellular stress responses and mitotic regulation. -
NEK6 Inhibitor
ZINC05007751 is a selective inhibitor of the NIMA-related kinase NEK6, exhibiting an IC50 of 3.4 μM. This compound demonstrates notable antiproliferative effects across various human cancer cell lines and synergizes with Cisplatin and Paclitaxel in BRCA2-mutated ovarian cancer models. ZINC05007751 displays high specificity for NEK6 and NEK1, with minimal activity against NEK2, NEK7, and NEK9, making it a valuable tool for studying NEK6-related pathways in cancer research. -
Hec1/Nek2 Inhibitor
Nek2/Hec1-IN-3 is a potent inhibitor of the Hec1/Nek2 interaction, specifically designed to disrupt the binding between these two proteins. This compound exhibits significant biological activity by interfering with the Nek2-mediated regulation of cell division, making it a valuable tool for research in neoplastic diseases and cancer biology. Its application in studying tumorigenesis and cell cycle dysregulation facilitates a deeper understanding of oncogenic pathways. -
Nek2 Inhibitor
JH295 hydrate is a selective and irreversible inhibitor of NIMA-related kinase 2 (Nek2), exhibiting an IC50 value of 770 nM. This compound targets cellular Nek2 by inducing alkylation at Cys22, while showing no activity against critical mitotic kinases such as Cdk1, Aurora B, or Plk1, thereby maintaining bipolar spindle assembly and the spindle assembly checkpoint. Additionally, JH295 hydrate functions as a click chemistry reagent, possessing an alkyne group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it valuable in various research applications. -
Nek2/Hec1 Inhibitor
Nek2/Hec1-IN-2 is a potent inhibitor of the Nek2 and Hec1 kinases. It effectively disrupts cell division processes, demonstrating inhibitory activity against cancer cell proliferation with an IC50 greater than 25 μM. This compound is valuable for research into mitotic regulation and therapeutic strategies targeting cancer cell growth. -
Nek2 Inhibitor
HCI-2184 is a potent Nek2 inhibitor with an IC50 value of 39.90 nM. This compound enhances the efficacy of Bortezomib by significantly inhibiting proteasome activity. HCI-2184 is valuable for research applications focused on cell cycle regulation and cancer therapeutics. -
Nek2 Inhibitor
Nek2-IN-6 is a selective inhibitor of never in mitosis (NIMA) related kinase 2 (Nek2), a critical regulator of mitotic processes. This compound demonstrates significant biological activity in inhibiting this kinase, making it valuable for exploring its role in cell division and related pathologies. Nek2-IN-6 is well-suited for research applications focused on cancer biology, particularly in studies examining the mitotic spindle assembly and its implications in tumorigenesis. -
NEK7 Inhibitor
NEK7-IN-1 is a potent inhibitor of NIMA-related kinase 7 (NEK7), exhibiting an IC50 of less than 100 nM. It effectively suppresses the release of IL-1β, with an IC50 of less than 50 nM. This compound is valuable for research into inflammatory responses and the molecular pathways involving NEK7. Its application extends to studies focused on cellular processes influenced by NEK7 modulation. -
Nek2 Inhibitor
Nek2-IN-5 is a potent and irreversible inhibitor of Nek2 (Never in mitosis gene a-related kinase 2). This compound features a clickable alkyne group, enabling it to undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-bearing molecules. Nek2-IN-5 is valuable in research applications focused on cell cycle regulation and cancer biology, providing insights into the role of Nek2 in cellular processes. -
MMP Inhibitor
Sucrose octasulfate is a matrix metalloproteinase (MMP) inhibitor that modulates cellular activities by regulating the extracellular matrix. It promotes the release of somatostatin-like immunoreactivity from gastric D cells, facilitating ulcer healing through increased endogenous somatostatin levels. This compound has demonstrated efficacy in improving wound closure in diabetic foot ulcers and venous leg ulcers, making it pertinent for research in chronic wound healing and gastrointestinal disorders. Additionally, sucrose octasulfate serves as a valuable pharmaceutical excipient in various therapeutic applications. -
MMP Inhibitor
Sucrose octasulfate sodium is a potent matrix metalloproteinase (MMP) inhibitor that enhances the release of somatostatin-like immunoreactivity (SLI) from gastric D cells. This compound promotes ulcer healing by increasing endogenous gastric somatostatin levels. Sucrose octasulfate sodium is utilized in research related to chronic wound healing and has shown significant efficacy in improving wound closure in diabetic foot ulcers and venous leg ulcers. Additionally, it serves as a useful pharmaceutical excipient in various applications. -
DHODH Inhibitor
DHODH-IN-17 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), with an IC50 value of 0.40 μM. This compound is pivotal for studying the metabolic pathways involved in acute myeloid leukemia (AML) and may aid in the development of targeted therapies for this condition. Its ability to inhibit DHODH highlights its potential use in cancer research, particularly in understanding tumor metabolism and proliferation. -
DHODH Inhibitor
DHODH-IN-23 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine synthesis pathway. This compound exhibits significant biological activity in cancer research, facilitating the exploration of metabolic pathways and their implications in tumorigenesis. DHODH-IN-23 serves as a valuable tool for studies aiming to elucidate the role of pyrimidine metabolism in cancer cell proliferation and survival. -
hDHODH Inhibitor
hDHODH-IN-13 is an inhibitor of human dihydroorotate dehydrogenase (hDHODH), with an IC50 value of 173.4 nM. This compound demonstrates significant potential in the investigation of inflammatory bowel disease (IBD) by modulating pyrimidine biosynthesis. hDHODH-IN-13 is a valuable tool for exploring therapeutic strategies targeting hDHODH in various disease models. -
DHODH Inhibitor
(E/Z)-Ginkgolic acid C17:2 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This compound, derived from Ginkgo biloba, demonstrates the ability to bind tightly to the target enzyme, mediating its biological activity. Its inhibitory effect on DHODH makes it a valuable reagent for studying cellular proliferation, autoimmune diseases, and potential anti-cancer strategies. -
hDHODH Inhibitor
hDHODH-IN-8 is a selective inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibiting an IC50 value of 16 nM. This compound demonstrates significant antiproliferative effects and possesses excellent solubility in aqueous solutions. hDHODH-IN-8 is particularly relevant for research exploring tumorigenesis, with potential implications in lymphoma studies. -
Dual RORγt/DHODH Inhibitor
RORγt/DHODH-IN-1 is a dual inhibitor targeting retinoic acid receptor-related orphan receptor gamma t (RORγt) and dihydroorotate dehydrogenase (DHODH). With IC50 values of 0.083 μM for RORγt and 0.172 μM for DHODH, this compound demonstrates significant potency. RORγt/DHODH-IN-1 has been shown to possess notable in vivo anti-inflammatory activity, making it a valuable tool for research in immunology and inflammation-related studies. -
Dual RORγt/DHODH Inhibitor
RORγt/DHODH-IN-3 is a dual inhibitor targeting both RORγt and dihydroorotate dehydrogenase (DHODH), exhibiting IC50 values of 0.098 μM for RORγt and 0.432 μM for DHODH. This compound demonstrates significant in vivo anti-inflammatory activity, making it a valuable tool for researchers investigating autoimmune diseases and other inflammatory conditions. Its dual mechanism of action positions it as a promising candidate for therapeutic development in these areas. -
hDHODH Inhibitor
hDHODH-IN-11 is a selective inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibiting an IC50 value of 7.2 nM. This compound demonstrates low cytotoxicity, making it suitable for in vitro studies. hDHODH-IN-11 is primarily utilized in research focused on acute myeloid leukemia (AML), contributing to the understanding of therapeutic targets within this malignancy. -
hDHODH Inhibitor
hDHODH-IN-10 is a selective and potent inhibitor of human dihydroorotate dehydrogenase (hDHODH), demonstrating an IC50 value of 10.9 nM. This compound exerts its biological activity through hydrogen bonding interactions with key residues, including Arg136 and Gln47. hDHODH-IN-10 effectively inhibits the proliferation of cancer cells and is useful for research applications related to various malignancies, such as acute myeloid leukemia (AML) and colorectal cancer. -
RORγt/DHODH Inhibitor
RORγt/DHODH-IN-2 is a potent dual inhibitor of RORγt and DHODH, targeting key pathways involved in immune regulation and inflammation. This compound exhibits significant biological activity that can be leveraged in the investigation of inflammatory bowel disease (IBD) and related immune disorders. Its dual action provides a valuable tool for research into therapeutic strategies aimed at modulating RORγt and DHODH activity in inflammatory contexts. -
DHODH Inhibitor
DHODH-IN-18 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), with an IC50 value of 0.2 nM. This compound effectively modulates the de novo pyrimidine biosynthesis pathway, making it a valuable tool in studies of cell proliferation and differentiation. DHODH-IN-18 is suitable for research applications in cancer biology and autoimmune disorders, where DHODH plays a critical role. -
DHODH Inhibitor
DHODH-IN-21 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor, exhibiting an IC50 value of 1.1 nM. This compound demonstrates significant anticancer activity, making it a valuable tool for research into acute myeloid leukemia (AML). Its high potency and specificity for DHODH facilitate investigations into the mechanistic roles of this enzyme in cancer biology. -
DHODH Inhibitor
DHODH-IN-22 is a highly selective and orally bioavailable inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 value of 0.3 nM. This compound demonstrates significant potential in the research of acute myelogenous leukemia (AML) by modulating pyrimidine synthesis and impacting cell proliferation. Its properties make DHODH-IN-22 a valuable tool for studying the biochemical pathways involved in AML and evaluating novel therapeutic strategies. -
DHODH Inhibitor
Indoluidin E is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme involved in the de novo pyrimidine biosynthesis pathway. This compound has demonstrated notable inhibitory effects on cancer cell proliferation, making it a valuable tool for cancer research. Its mechanistic action allows for potential applications in studying metabolic pathways and developing therapeutic strategies targeting DHODH in various malignancies. -
hDHODH Inhibitor
hDHODH-IN-9 is a specific inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 value of 0.34 μM. This compound exhibits significant cytotoxic activity against MCF-7 and A375 cancer cell lines, showcasing its potential for selective targeting in cancer research. hDHODH-IN-9 serves as a valuable tool for studies investigating the role of hDHODH in tumorigenesis and cancer therapy. -
DHODH Inhibitor
DHODH-IN-34 is a selective inhibitor of human dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 value of 13 nM. This compound is particularly valuable for researching RNA viruses, including measles virus and chikungunya virus, due to its ability to disrupt nucleotide synthesis pathways critical for viral replication. Researchers can leverage DHODH-IN-34 to investigate therapeutic strategies against these viral infections. -
Glutamine Synthetase Inhibitor; Convulsant
L-Methionine-DL-sulfoximine is a highly specific and irreversible inhibitor of glutamine synthetase, which significantly affects astroglial metabolism and morphology. This compound also demonstrates potent convulsant properties. L-Methionine-DL-sulfoximine has been utilized in research to inhibit glutamine-dependent neuronal toxicity in vitro and to study the mechanisms underlying convulsive seizures. Additionally, it enhances the rate of fixed nitrogen release in cyanobacteria, making it a valuable tool for applications in biofertilizer research. -
Tyrosinase Inhibitor
Cepharadione B is a natural tyrosinase inhibitor derived from the leaves of Piper sanctum, exhibiting an IC50 value of 170 μM. This compound demonstrates significant inhibitory effects on cell growth in various cancer cell lines, including A-549, SK-OV-3, SK-MEL-2, XF-498, and HCT-15. Cepharadione B is valuable for research exploring pigmentation processes, melanoma, and potential therapeutic interventions against cancer. -
Thrombin/ Factor Xa Inhibitor
Ciraparantag is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants. This compound effectively neutralizes the effects of low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. Its unique mechanism makes Ciraparantag a valuable tool for research focused on anticoagulation reversal and hemostasis. -
Thrombin/Factor Xa Inhibitor
Ciraparantag acetate is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants, including low molecular weight heparins, unfractionated heparins, and certain direct oral anticoagulants, excluding vitamin K antagonists (VKAs). Its primary mechanism targets the coagulation pathway, facilitating the restoration of normal hemostasis in clinical situations where anticoagulation reversal is necessary. Ciraparantag acetate is valuable in research applications focused on anticoagulation management and hemostatic balance in cardiovascular studies. -
Thrombin Inhibitor
Edoxaban impurity 4 is a structural impurity related to Edoxaban, a selective and potent thrombin inhibitor. It demonstrates significant biological activity and is primarily utilized in research applications focusing on anticoagulation strategies. Edoxaban itself serves as an effective anticoagulant, with its mechanistic role in inhibiting factor Xa contributing to therapeutic approaches for stroke prevention and other thromboembolic disorders. -
Thrombin/Factor Xa Inhibitor
Ciraparantag TFA is a potent thrombin and factor Xa inhibitor utilized as a broad-spectrum reversal agent for anticoagulants. It effectively antagonizes the effects of various anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and specific direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. This compound is significant for research applications focused on enhancing hemostatic management in patients receiving anticoagulant therapy. -
Thrombin/Factor Xa/Trypsin/Papain Inhibitor
Bacithrocin D is a potent inhibitor of key proteases, specifically targeting thrombin, factor Xa, trypsin, and papain. It effectively prolongs clotting time, making it valuable in studies related to coagulation and hemostasis. Bacithrocin D demonstrates IC50 values of 124 μM for thrombin, 9 μM for factor Xa, 0.85 μM for trypsin, and a remarkable 0.01 μM for papain, showcasing its high potency against these proteases. This reagent is useful for investigating protease-related pathways and developing therapeutic strategies in anticoagulation research. -
Thrombin Inhibitor
Bacithrocin A is a potent thrombin inhibitor that also targets factor Xa, trypsin, and papain, demonstrating IC50 values of 48 μM, 13 μM, 0.65 μM, and 0.02 μM, respectively. This compound is of particular interest in the study of coagulation processes and the development of anticoagulant therapies. Its broad-spectrum inhibitory activity makes it a valuable reagent for biological research focused on protease activity modulation and hemostasis. -
Thrombin Inhibitor
Bacithrocin C is a potent thrombin inhibitor that effectively targets thrombin, factor Xa, trypsin, and papain, exhibiting IC50 values of 80 μM, 15 μM, 1.3 μM, and 0.02 μM, respectively. This compound demonstrates significant inhibitory activity, making it a valuable tool for research in coagulation pathways and protease-related studies. It is suitable for applications focused on understanding thrombotic processes and developing antithrombotic strategies. -
Thrombin Inhibitor
Bacithrocin B is a potent thrombin inhibitor that also targets factor Xa, trypsin, and papain. It exhibits inhibitory activity with IC50 values of 84 μM for thrombin, 17 μM for factor Xa, 1.7 μM for trypsin, and 0.02 μM for papain. This compound is valuable for research applications aiming to study coagulation processes and enzyme dynamics in various biological systems. -
MMP Inhibitor
Apigenin-7-glucuronide is a potent inhibitor of Matrix Metalloproteinases (MMP), demonstrating IC50 values of 12.87 µM for MMP-3, 22.39 µM for MMP-8, 17.52 µM for MMP-9, and 0.27 µM for MMP-13. This compound's ability to modulate MMP activity makes it valuable for investigations into extracellular matrix regulation, tissue remodeling, and various inflammatory conditions. Researchers may utilize Apigenin-7-glucuronide in studies aiming to explore therapeutic interventions in diseases associated with MMP dysregulation. -
MMP Inhibitor
Luteolin 7-O-glucuronide is a potent inhibitor of Matrix Metalloproteinases (MMPs), demonstrating IC50 values of 17.63 μM for MMP-1, 7.99 μM for MMP-3, 11.42 μM for MMP-8, 12.85 μM for MMP-9, and 0.03 μM for MMP-13. This compound is valuable for research investigating the regulation of MMP activity, which plays a critical role in extracellular matrix remodeling and various pathological conditions. It is suitable for applications in studies related to cancer metastasis, tissue repair, and inflammatory disorders. -
Thrombin Inhibitor
Argatroban monohydrate is a direct and selective inhibitor of thrombin. It plays a critical role in anticoagulation therapy, particularly for patients with heparin-induced thrombocytopenia. Argatroban is widely used in research to study coagulation pathways and evaluate potential therapeutic approaches for thrombotic disorders. -
Tyrosinase Inhibitor
α-Arbutin (4-Hydroxyphenyl α-D-glucopyranoside) is a potent tyrosinase inhibitor known for its ability to reduce melanin production, making it a valuable agent in skin lightening applications. This compound is of significant interest in research surrounding hyperpigmentation disorders, various cancer types, central nervous system disorders, osteoporosis, and diabetes, offering potential therapeutic insights into these conditions. Its mechanism of action provides a basis for exploring innovative treatments and understanding skin-related pathologies.
